InflammoGen is focused on the field of Chronic Upper Respiratory
Inflammatory Diseases, such as Asthma and COPD. With very strong
IPs and a thorough patentability search completed, InflammoGen,
in conjunction with its partners, will research and develop
a novel and superior class of anti-inflammatory drugs.
InflammoGen
will look to expolit its opportunities in a market dominated
by corticosteroids, by introducing a non-steroid based drug,
with established safety and tolerability. In addition to Asthma
and COPD, InflammoGen's technology has shown great promise
in other areas of research. |
